ILARIA COLOMBO

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (18)

Collaborators (6)

ANASTASIOS STATHIS

Head of Research Service and Scientific Head Clinical Trial Unit

Istituto Cantonale di Patologia

Lucia Manganaro

Stefanie Hayoz

Head of Statistics

Maria Del Grande

University Hospital Basel

Silke Gillessen

The University of Manchester

UNITED KINGDOM

Stefania Rizzo

Università del Salento

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

ILARIA COLOMBO

Research Interests

Explore related searches

Contact this professor

Articles (18)

Collaborators (6)

ANASTASIOS STATHIS

Lucia Manganaro

Stefanie Hayoz

Maria Del Grande

Silke Gillessen

Stefania Rizzo

Make your next move.

ILARIA COLOMBO

Research Interests

Explore related searches

Contact this professor

Articles (18)

A Retrospective Assessment of Computed Tomography-Based Body Composition and Toxicity in Ovarian Cancer Patients Treated with PARP Inhibitors

Safety of antibody-drug conjugates in gynecologic cancers: current evidence and management approaches

A systematic review of phase I trials in patients with ovarian cancer

Can we learn from failures? A systematic review of phase III trials in platinum-resistant ovarian cancer

TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)

Clinical relevance of circulating tumor DNA in ovarian cancer: current issues and future opportunities

The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer

SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial

The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities

Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery

Whole-Body Composition Features by Computed Tomography in Ovarian Cancer: Pilot Data on Survival Correlations

Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer

Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?

Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents

A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors

Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment

Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies

Collaborators (6)

ANASTASIOS STATHIS

Lucia Manganaro

Stefanie Hayoz

Maria Del Grande

Silke Gillessen

Stefania Rizzo

Make your next move.